Brochure | March 1, 2022

Early Phase Manufacture And Process Development

Source: Oxford Biomedica

Oxford Biomedica (OXB) has established the leading serum free, single use, commercial process for the manufacture of cGMP lentiviral vectors. We offer our partners the opportunity to leverage that experience and knowledge to achieve rapid progress, from product development to released cGMP batch.

Speed to clinical studies is highly desirable in drug development, and in gene therapy this can be challenging. We offer rapid entry to clinical trials through the application of a tried and tested process, allied to deep knowledge of lentiviral vector process development, enabling our partners to save time and money.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online